Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

bination with bendamustine and rituximab in R/R CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™-17, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment (a high unmet need population). The primary endpoint of the study is the overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company plans to complete enrollment for this study before year end 2013.
  • Phase III study of ibrutinib versus temsirolimus in R/R MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a monotherapy versus temsirolimus in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression-free-survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in patients with newly diagnosed MCL. The primary endpoint of the study is progression-free-survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with R/R MCL who progress after bortezomib therapy,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
    (Date:9/30/2014)... September 30, 2014 The report ... Market Size, Share, Growth and Forecast, 2007 - 2017," ... worth USD 20.8 billion in 2012 and is further ... at a CAGR of 7.3% from 2012 to 2017. ... various health purposes, especially to prevent chronic diseases that ...
    (Date:9/30/2014)... 30. September 2014 ... Acutus Medical, ... minimal-invasives 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit ... zu komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen ... einer zusätzlichen Finanzierung über 26,2 Mio. ...
    Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
    ... to dramatically reduce the risk of cancer ... EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ ... tablets to,patients receiving placebo in a major ... showed participants with Kit-positive,gastrointestinal stromal tumors treated ...
    ... 2007 - Immunicon,Corporation (NASDAQ-GM:IMMC) will exhibit at ... the Los Angeles,Convention Center, April 15 to ... the new CellCapture(TM) CTC,Mouse/Rat Kit and the ... Pharma Services offers assay development and clinical,trial ...
    Cached Medicine Technology:Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 2Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 3Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 4Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 6Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 7Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4
    (Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
    (Date:9/30/2014)... NV (PRWEB) September 30, 2014 EverStryke ... a free introduction to SurvivalLife.com along with a free book ... the attention of Shane Michaels, prompting an investigative review. ... well-known people in the survival and preparation niche, and this ... of the great classes and survival products that Joe offers ...
    (Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
    (Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
    (Date:9/30/2014)... 30, 2014 Bifidobacteria, the primary bacteria ... poor diet, and stress, so a high Bifido probiotic ... of Ultimate Flora™ Men’s Complete contains 90 ... 7 Bifidobacteria strains to support a healthy large intestine ... up, and 32 billion cultures from 7 Lactobacillus strains ...
    Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Regenerative Medicine Solutions Expanding 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
    ... Institutes of Health in the United States has evaluated the ... and the average quantity of alcohol drunk per occasion and ... well as all cancers. The analysis is based on ... US, assessing more than 300,000 subjects who suffered over 8,000 ...
    ... age, forgetfulness and other signs of memory loss sometimes appear, ... that they may be experiencing early symptoms of Alzheimer,s disease ... 65 and older. But even when early memory problems ... variable. Some patients are at high risk while others are ...
    ... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... a lumpectomy have significantly fewer recurrences and, consequently, greater ... research says. The study also noted no ... as deaths from any cause were also reduced substantially. ...
    ... recent UT Southwestern Medical Center study found that estrogen regulates ... in specific parts of the brain may lead to obesity. ... Deborah Clegg, associate professor of internal medicine and senior author ... . "We hadn,t previously thought of sex hormones as being ...
    ... HealthDay Reporter , WEDNESDAY, Oct. 19 (HealthDay News) ... after birth interferes with development of the brain,s cerebellum, ... new research finds. For the study, researchers analyzed ... weeks, gestation) at two medical centers, the University of ...
    ... Department of Defense (DoD) Congressionally Directed Medical Research ... has awarded a $19.7 million grant to the ... consortium that will improve the quality of life ... combat. The Bridging Advanced Developments for ...
    Cached Medicine News:Health News:Association of quantity of alcohol and frequency of consumption with cancer mortality 2Health News:Combination of available tests helps predict Alzheimer's disease risk 2Health News:Breast Radiation After Lumpectomy Saves Lives: Study 2Health News:UT Southwestern study shows estrogen works in the brain to keep weight in check 2Health News:Steroids Given to Preemies May Harm Brain Growth: Study 2Health News:Steroids Given to Preemies May Harm Brain Growth: Study 3Health News:University of Delaware to lead DoD orthopaedic rehabilitation consortium 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: